This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over.
Introduction: The overall survival of patients with multiple myeloma (MM) has changed dramatically in the last decade. MM remains an incurable plasma cell disorder but immunotherapy with monoclonal antibodies (MoAbs) ...
The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma...
New classes of drugs including the proteasome inhibitors (PI) bortezomib and, more recently, carfilzomib and the immunomodulatory agent lenalidomide have shown improved outcomes for multiple myeloma (MM) patients during the past decade.
The FDA has granted approval for Empliciti (elotuzumab), from BMS/Abbvie, in combination with two other therapies to treat people with...
Introduction: Proteasome inhibitors and immunomodulatory drugs have contributed to the dramatic improvement in survival for patients with myeloma over the past decades.
The FDA has permitted marketing of ClonoSEQ assay, a next generation sequencing (NGS)-based test, from Adaptive Biotechnologies, for minimal residual...
The National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting Revlimid (lenalidomide) from Celgene, for people...